Boostrix is a 3 in 1 shot (tetanus, diphtheria, and acellular pertussis) used as a booster dose (Tdap) for children and adults 10 years and older (see GlaxoSmithKline product insert for recommended schedule and other indications).
- Vaccine ingredients: Aluminum hydroxide, sodium chloride, polysorbate 80, modified Latham medium derived from bovine casein, Fenton medium containing a bovine extract, formaldehyde, modified Stainer-Scholte liquid medium, glutaraldehyde.
- Estimated Efficacy: Antibody responses to diphtheria were tested one month following administration of a single booster dose of Boostrix in adolescents between the ages of 10 and 18 years. 99.9 percent of vaccine recipients were found to have blood antibody levels considered protective against diphtheria. When tested one month following administration in persons between 19 and 64 years of age, 98.2 percent of vaccine recipients were noted to have blood antibody levels considered to be protective against diphtheria.
- Use with Other Vaccines In clinical trials, Boostrix was given with inactivated influenza vaccine (Fluarix) and the meningococcal vaccine (Menactra). In both clinical trials, the antibody level for the pertussis component was determined to be lowered. There is no information in the product insert about the safety or effectiveness of giving Boostrix simultaneously with live influenza, MMR, varicella, HPV, hepatitis B, hepatitis A, inactivated polio or other vaccines.
BOOSTRIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. Female rats and rabbits vaccinated with BOOSTRIX was reported to have no effect on fertility.
